Skip to main content

Advertisement

SpringerLink
Log in

RETRACTED ARTICLE: Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis

  • Research Article
  • Published:
Tumor Biology

This article was retracted on 20 April 2017

Abstract

Survivin has been widely reported to play a role in diagnosis and prognosis of bladder cancer patients. However, published data on this subject are heterogeneous. Here, we conducted a meta-analysis to obtain a complete evaluation of the association between survivin and recurrence-free survival (RFS), disease-specific survival (DSS), overall survival (OS), and odds ratio (OR) in bladder cancer patients. Published studies on this subject were selected for further assessment by online articles in PubMed, MEDLINE, EMBASE, and OVID databases. Pooled hazard ratios (HR) with 95 % confidence interval (95 % CI) were estimated. Funnel plots were used to evaluate the publication bias. As well, heterogeneity and sensitivity were analyzed. In this meta-analysis, we included 13 studies with the total number of 1,963 patients. Positive survivin expression in bladder cancer was associated with a poor RFS (HR, 1.831; 95 % CI, 1.344–2.49), DSS (HR, 1.721; 95 % CI, 1.477–2.004), or OS (HR, 1.753; 95 % CI, 1.092–2.816) in patients. In addition, a significant association between expression of survivin and age (OR, 0.641; 95 % CI, 0.416–0.987) as well as stage (OR, 0.37; 95 % CI, 0.190–0.750) was revealed. Heterogeneity was observed among the included studies with RFS (x 2 = 29.58, p = 0.009, I 2 = 52.7 %), OS (x 2 = 15.67, p = 0.008, I 2 = 68.1 %), and stage (x 2 = 11.97, p = 0.035, I 2 = 58.2 %). There was no publication bias according to Begg’s and Egger’s tests except for studies with gender. Furthermore, sensitivity analysis obtained the source of heterogeneity and confirmed opposite results of some studies. This study suggests that expression of survivin indicates poor prognosis in older patients and muscle invasive or advanced stage in bladder cancer. Survivin expression could be used in identifying a subgroup of patients with potential to benefit from a targeted therapy against survivin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E. Cancer statistics 2004. CA Cancer J Clin. 2004;54:8–29.

    Article  PubMed  Google Scholar 

  2. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol. 2008;18:1–8.

    Article  PubMed  Google Scholar 

  3. Sah NK, Khan Z, Khan GJ, Bisen PS. Structural, functional and therapeutic biology of survivin. Cancer Lett. 2006;244:164–71.

    Article  CAS  PubMed  Google Scholar 

  4. Rödel F, Sprenger T, Kaina B, Liersch T, Rödel C, Fulda S, et al. Survivin as a prognostic/predictive marker and molecular target in cancer therapy. Curr Med Chem. 2012;19:3679–88.

    Article  PubMed  Google Scholar 

  5. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin Ther Targets. 2008;12:463–76.

    Article  CAS  PubMed  Google Scholar 

  6. Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc. 2001;34:207–12.

    Article  CAS  PubMed  Google Scholar 

  7. Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, et al. Survivin initiates procaspase-3/p21 complex formation as a result of interaction with CDK4 to resist Fas-mediated cell death. Oncogene. 2000;19:1346–51.

    Article  CAS  PubMed  Google Scholar 

  8. Zhang LQ, Wang J, Jiang F, Xu L, Liu FY, Yin R. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS One. 2012;7(e3):4100.

    Google Scholar 

  9. Li C, Li Z, Zhu M, Zhao T, Chen L, Ji W, et al. Clinicopathological and prognostic significance of survivin over-expression in patients with esophageal squamous cell carcinoma: a meta-analysis. PLoS One. 2012;7:e44764.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Li Y, Tan BB, Fan LQ, Zhao Q, Liu Y, Wang D. Expression of COX-2, survivin in regional lymph node metastases of gastric carcinoma and the correlation with prognosis. Hepatogastroenterology. 2010;57:1435–41.

    CAS  PubMed  Google Scholar 

  11. Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res. 2007;67:5999–6002.

    Article  CAS  PubMed  Google Scholar 

  12. Margulis V, Lotan Y, Montorsi F, Shariat SF. Predicting survival after radical cystectomy for bladder cancer. BJU Int. 2008;102:15–22.

    Article  PubMed  Google Scholar 

  13. Athanassiadou AM, Patsouris E, Tsipis A, Gonidi M, Athanassiadou P. The significance of Survivin and Nectin-4 ex-pression in the prognosis of breast carcinoma. Folia Histochem Cytobiol. 2011;49:26–33.

    Article  CAS  PubMed  Google Scholar 

  14. Nakanishi K, Tominaga S, Hiroi S, Kawai T, Aida S, Kasamatsu H, et al. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch. 2002;441(6):559–63.

    Article  CAS  PubMed  Google Scholar 

  15. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001;8:705–19.

    Article  Google Scholar 

  16. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;7:8–16.

    Google Scholar 

  17. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.

    Article  CAS  PubMed  Google Scholar 

  18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Xi RC, Sheng YR, Chen WH, Sheng L, Gang JJ, Tong Z, et al. Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer. J Surg Oncol. 2013;107(5):550–4.

    Article  CAS  PubMed  Google Scholar 

  20. Gradilone A, Petracca A, Nicolazzo C, Gianni W, Cortesi E, Naso G, et al. Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int. 2010;106:710–5.

    Article  CAS  PubMed  Google Scholar 

  21. Weiss C, von Römer F, Capalbo G, Ott OJ, Wittlinger M, Krause SF, et al. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys. 2009;74(5):1455–60.

    Article  CAS  PubMed  Google Scholar 

  22. Skagias L, Politi E, Karameris A, Sambaziotis D, Archondakis A, Ntinis A, et al. Survivin expression as a strong indicator of recurrence in urothelial bladder cancer. Anticancer Res. 2009;29:4163–7.

    PubMed  Google Scholar 

  23. Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol. 2009;182:78–84.

    Article  PubMed  Google Scholar 

  24. Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res. 2009;15:7012–9.

    Article  CAS  PubMed  Google Scholar 

  25. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer. 2007;109:1106–13.

    Article  CAS  PubMed  Google Scholar 

  26. Pina-Cabral L, Santos L, Mesquita B, Amaro T, Magalhães S, Criado B. Detection of survivin mRNA in urine of patients with superficial urothelial cell carcinomas. Clin Transl Oncol. 2007;9:731–6.

    Article  CAS  PubMed  Google Scholar 

  27. Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology. 2007;70:482–6.

    Article  PubMed  Google Scholar 

  28. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007;8:128–36.

    Article  CAS  PubMed  Google Scholar 

  29. Als AB, Dyrskjøt L, von der Maase H, Koed K, Mansilla F, Toldbod HE, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res. 2007;13:4407–14.

    Article  CAS  PubMed  Google Scholar 

  30. Yin W, Chen N, Zhang Y, Zeng H, Chen X, He Y, et al. Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder. Mod Pathol. 2006;19:1487–97.

    CAS  PubMed  Google Scholar 

  31. Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. J R Stat Soc A. 1988;151:419–63.

    Article  Google Scholar 

  32. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by China Scholarship Council. We were also very thankful to the support of Sun lab staff for their valuable advice.

Conflict of interest

The authors state that there are no conflicts of interest to disclose.

Author information

Authors and Affiliations

  1. Department of Surgery, University of Toronto, Toronto, ON, Canada

    Shunzeng Lv, Ekaterina Turlova & Hong-Shuo Sun

  2. Department of Medicine, Shanghai Jiaotong University, Shanghai, China

    Shigang Zhao

  3. Department of Medicine, Shandong University, Jinan Shandong, China

    Huihui Kang & Mingzhi Han

Authors
  1. Shunzeng Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ekaterina Turlova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shigang Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Huihui Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mingzhi Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hong-Shuo Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hong-Shuo Sun.

Additional information

The Publisher and Editor retract this article in accordance with the recommendations of the Committee on Publication Ethics (COPE). After a thorough investigation we have strong reason to believe that the peer review process was compromised.

An erratum to this article can be found online at http://dx.doi.org/10.1007/s13277-017-5487-6.

About this article

Cite this article

Lv, S., Turlova, E., Zhao, S. et al. RETRACTED ARTICLE: Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis. Tumor Biol. 35, 1565–1574 (2014). https://doi.org/10.1007/s13277-013-1216-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1216-y

Keywords

Search

Navigation